Sort
10,766 grants matching “checkpoint inhibitor”
ER stress-driven IRE1a-XBP1 signaling in lung cancer
$663,481Vivek Mittal · Weill Medical Coll Of Cornell Univ · R01 · FY2025 · CA
Combining immunotherapy with molecularly targeted radiation therapy
$663,343Lawrence Fong · University Of California, San Francisco · R01 · FY2023 · CA
Understanding IDH mutant gliomas
$663,335Jing Wu · Division Of Basic Sciences - Nci · ZIA · FY2023 · CA
Improving emergency care and outcomes of immune-related adverse events: The immune-related emergency disposition index (IrEDi)
$663,212Cielito C Reyes-Gibby · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
A precision oncology approach to integrating of tumor microenvironment suppressive cell modulators to enhance antitumor immunity
$662,979Dung T Le · Johns Hopkins University · P01 · FY2022 · CA
DNA repair gene mutations and prostate cancer
$662,863Binghui Shen · Beckman Research Institute/City Of Hope · R01 · FY2024 · CA
Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors
$662,835Albert Folch · University Of Washington · R01 · FY2025 · CA
Evolution of gliomas during treatment and resistance
$662,723Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Multiscale analysis of metabolic inflammation as a driver of breast cancer
$662,592Gerald V Denis · Boston University Medical Campus · U01 · FY2022 · CA
Exploiting the VISTA Pathway to Prevent Acute GVHD and Control Steroid Refractory Disease
$662,404Bruce R. Blazar · University Of Minnesota · R01 · FY2022 · HL
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$662,338Cesar M Castro · Massachusetts General Hospital · R01 · FY2021 · CA
Impact of Circulating Myeloid Cell Clusters on Anti-Tumor Immunity
$662,308Sharon S Evans · Roswell Park Cancer Institute Corp · R01 · FY2024 · CA
Activating Cell Death Pathways in Breast Cancer Cells
$662,171Stanley Lipkowitz · Division Of Clinical Sciences - Nci · ZIA · FY2018 · CA
Autoimmunity in Cardiopulmonary Toxicities from Radiotherapy and Immunotherapy
$661,613Bo Lu · Thomas Jefferson University · R01 · FY2020 · CA
Credentialing a Cross-Species Platform to Investigate Cancer Therapy-Associated Cardiovascular Toxicity
$661,594Iris Z Jaffe · Tufts Medical Center · R01 · FY2020 · CA
Tumor and immune determinants of effective anti-tumor immunity in renal cell carcinoma
$661,522David Braun · Yale University · R37 · FY2025 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer
$661,394Jia Wu · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Leveraging DNA damage repair pathways as therapeutic targets in womens cancers
$661,211Jung-Min Lee · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Develop a novel therapy with immuno- and onco-targeting dual efficacies to treat the triple negative breast cancer
$661,072Deyu Fang · Northwestern University At Chicago · R01 · FY2025 · CA
Targeting the immunosuppressive tumor microenvironment to enhance efficacy of radiotherapy and immuno-radiotherapy for oral cancer
$661,043Andrew Sikora · University Of Tx Md Anderson Can Ctr · U01 · FY2022 · DE
Targeting the Mitochondria to Overcome Resistance to Immune Checkpoint Inhibition in Malignant Pleural Mesothelioma
$660,954Robert Taylor Ripley · Baylor College Of Medicine · R37 · FY2024 · CA
Understanding efficacy and FE(II)-Promoted Activation of 1,2,4-Trioxolanes in cancer
$660,920Eric Collisson · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Targeting tumoral Lactobacillus iners to improve outcomes in cervical cancers
$660,742Lauren Elizabeth Colbert · University Of Tx Md Anderson Can Ctr · R37 · FY2024 · CA
A Quantitative PET/CT Research Resource for Co-Clinical Imaging of Lung Cancer Therapies
$660,269Paul E Kinahan · University Of Washington · U24 · FY2021 · CA
Synthetic lethalities to cell cycle disruption in glioma
$660,022Rameen Beroukhim · Dana-Farber Cancer Inst · R01 · FY2023 · CA